Effectiveness of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine on Symptomatic SARS-CoV-2 Infection and COVID-19-related Hospitalizations, Mortality, and Long-term Consequences in Brazil: a Real-world Evidence Study
Latest Information Update: 10 Nov 2023
Price :
$35 *
At a glance
- Drugs Tozinameran (Primary) ; AZD 1222; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech
- Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- 03 Nov 2023 Status changed from active, no longer recruiting to completed.
- 20 Feb 2023 Planned End Date changed from 1 Oct 2023 to 20 Jun 2024.
- 20 Feb 2023 Status changed from recruiting to active, no longer recruiting.